Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: Evaluation of formulation and delivery device

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 9, 2012, Pages 1254-1263

  Hindle, Michael ^a   Longest, P Worth ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Virginia Commonwealth University   (United States)

Author keywords

combination particles; enhanced excipient growth; hygroscopic growth; nanoaerosols; respiratory drug delivery

Indexed keywords

BUDESONIDE; CITRIC ACID; MANNITOL; SALBUTAMOL SULFATE; SODIUM CHLORIDE;

AEROSOL; ARTICLE; CHEMICAL REACTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENERATOR; INHALATIONAL DRUG ADMINISTRATION; INHALER; PARTICLE SIZE;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUNG; MANNITOL; METERED DOSE INHALERS; MODELS, ANATOMIC; NANOPARTICLES; PARTICLE SIZE; RESPIRATORY MUCOSA; SODIUM CHLORIDE;

EID: 84864668511     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01476.x     Document Type: Article

References (26)

1. Longest PW, et al,. Developing a better understanding of spray system design using a combination of CFD modeling and experiment. In:, Dalby RN, et al., eds. Proceedings of Respiratory Drug Delivery 2008. River Grove, IL: Davis Healthcare International Publishing, 2008: 151-163.
2. Hindle M, Longest PW,. Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model. Pharm Res 2010; 27: 1800-1811.
3. Zhang Y, et al,. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med 2007; 20: 227-235. (Pubitemid 47463180)
4. Cheng YS, et al,. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001; 14: 255-266. (Pubitemid 32744357)
5. Leach CL, et al,. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-1353. (Pubitemid 29011427)
6. Byron PR, et al,. Stepping into the trachea with realistic physical models: uncertainties in regional drug deposition from powder inhalers. Respir Drug Deliv 2010 2010; 1: 215-224.
7. Newman SP, Busse WW,. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293-304.
8. Kamada AK, et al,. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996; 153: 1739-1748. (Pubitemid 26187895)
9. Borgstrom L, et al,. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006; 19: 473-483. (Pubitemid 46067766)
10. Xi J, Longest PW,. Transport and deposition of micro-aerosols in realistic and simplified models of the oral airway. Ann Biomed Eng 2007; 35: 560-581. (Pubitemid 46448162)
11. Jaques PA, Kim CS,. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol 2000; 12: 715-731.
12. Longest PW, et al,. Characterization of nanoaerosol size change during enhanced condensational growth. Aerosol Sci Technol 2010; 44: 473-483.
13. Longest PW, Hindle M,. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Technol 2011; 45: 884-899.
14. Longest PW, Hindle M,. CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro data. J Aerosol Sci 2010; 41: 805-820.
15. Tian G, et al,. Characterization of respiratory drug delivery with enhanced condensational growth (ECG) using an individual path model of the entire tracheobronchial airways. Ann Biomed Eng 2011; 39: 1136-1153.
16. Longest P, Hindle M,. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results. Pharm Res 2011 DOI: 10.1007/s11095-011-0596-1.
17. Thudium J,. Water-uptake and equilibrium sizes of aerosol-particles at high relative humidities-their dependence on composition of water-soluble material. Pure Appl Geophys 1978; 116: 130-148.
18. Haenel G, Zankl B,. Aerosol size and relative humidity: water uptake by mixtures of salts. Tellus 1979; 31: 478-486.
19. Gonda I, Byron PR,. Perspectives on the biopharmacy of inhalation aerosols. Drug Dev Ind Pharm 1978; 4: 243-259. (Pubitemid 8331380)
20. Hickey AJ, Martonen TB,. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res 1993; 10: 1-7. (Pubitemid 23020830)
21. Hickey AJ, et al,. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 1990; 79: 1009-1014. (Pubitemid 20376195)
22. Hindle M, et al,., ed. Proceedings of Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, Inc., 1998: 97-102.
23. Dalby R, et al,. A review of the development of Respimat soft mist inhaler. Int J Pharm 2004; 283: 1-9. (Pubitemid 39200921)
24. Longest PW, Hindle M,. Evaluation of the Respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv 2009; 22: 99-112.
25. Longest PW, et al,. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol Sci Technol 2007; 41: 952-973. (Pubitemid 47394484)
26. Zierenberg B,. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12 (Suppl. 1): S19-S24. (Pubitemid 29471418)